DaVita found using ticker (DVA) have now 8 analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The range between the high target price and low target price is between 150 and 112 calculating the average target price we see 127. Given that the stocks previous close was at 110.06 this would imply there is a potential upside of 15.4%. The 50 day MA is 112.3 and the 200 day MA is 116.22. The company has a market cap of $10,493m. Find out more information at: https://www.davita.com
The potential market cap would be $12,108m based on the market concensus.
DaVita provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners and changed its name to DaVita in September 2016. DaVita was incorporated in 1994 and is headquartered in Denver, Colorado.
